June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Safety Margins of Anti-VEGF Therapy using Treat and Extend Treatment Protocol – Lessons from the COVID-19 Pandemic
Author Affiliations & Notes
  • Ana Navarrete
    Ophthalmology, Hadassah Medical Center, Jerusalem, Jerusalem, Israel
  • Brice Vofo
    Ophthalmology, Hadassah Medical Center, Jerusalem, Jerusalem, Israel
  • Katherine Matos
    Ophthalmology, Hadassah Medical Center, Jerusalem, Jerusalem, Israel
  • Antonio Rivera
    Ophthalmology, Hadassah Medical Center, Jerusalem, Jerusalem, Israel
  • Jaime Levy
    Ophthalmology, Hadassah Medical Center, Jerusalem, Jerusalem, Israel
  • Itay Chowers
    Ophthalmology, Hadassah Medical Center, Jerusalem, Jerusalem, Israel
  • Footnotes
    Commercial Relationships   Ana Navarrete, None; Brice Vofo, None; Katherine Matos, None; Antonio Rivera, None; Jaime Levy, None; Itay Chowers, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 421. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ana Navarrete, Brice Vofo, Katherine Matos, Antonio Rivera, Jaime Levy, Itay Chowers; Safety Margins of Anti-VEGF Therapy using Treat and Extend Treatment Protocol – Lessons from the COVID-19 Pandemic. Invest. Ophthalmol. Vis. Sci. 2021;62(8):421.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To analyze the consequences of delaying intravitreal (IVI) anti-vascular endothelial growth factor (VEGF) therapy in patients under treat-and-extend (TAE) protocol.

Methods : A retrospective review of medical records of a consecutive group of patients receiving IVI using TAE protocol before and during the COVID-19 pandemic. Data collected included diagnosis, demographics, treatment schedule, compound used and anatomical outcome according to spectral-domain optical coherence tomography (SD-OCT).

Results : A total of 923 eyes (691 patients) were included; 58.8% (543 eyes) were treated for neovascular age-related macular degeneration (nvAMD), 25% (231 eyes) had diabetic macular edema (DME), and 16.2% (149 eyes) with retinal vein occlusion (RVO). The average patient age (±SD) was 74.5 ± 11.7 years. The Female/male ratio was 1.08:1. Delayed therapy during the pandemic (?7 days) occurred in 56.3% of the eyes. This included 56.2%, 61.5%, 49.0% of nvAMD, DME and RVO patients respectively. The overall average delay (±SD) was 15.3±23.4 days. RVO patients were on average less late (9.3±16.1 days) compared to nvAMD (15.8±23.8) and DME (18.2±25.6) eyes (P=0.002). Multivariate analysis showed that in nvAMD duration of the disease and type of anti-VEGF were predictors of the number of days late (P=0.011 and 0.019). In eyes ? 7days late, 45.7%, 58.5%, and 58.9% of nvAMD, DME, and RVO eyes respectively showed an increase in central subfield thickness (CST). Worsening was related to absolute numbers of days late, and not to the percentage of delay of the recommended interval. A positive correlation was found between delay to treatment and an increase in CST.

Conclusions : Delaying IVI in eyes under TAE regimen was common during the COVID-19 pandemic. These delays were associated with macular thickening having potential visual consequences.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×